Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The target Solute carrier family 2, facilitated glucose transporter member 1 (GLUT-1) and ocular surface matrix components refers to the functional interaction between the primary glucose transporter of the eye and the structural proteins of the corneal basement membrane [2, 8]. GLUT-1 is a uniporter protein highly expressed in the corneal epithelium and endothelium, where it facilitates the passive transport of glucose to support the metabolic needs of the avascular cornea [3, 6]. The ocular surface matrix components, including collagen and fibronectin, provide the structural scaffold necessary for epithelial cell adhesion and basement membrane integrity [7, 8]. This dual-target profile is the primary mechanism for carboxymethylcellulose (CMC), a common lubricant in artificial tear formulations [2, 8]. CMC binds to GLUT-1 through its glucopyranose subunits and anchors to matrix proteins, which significantly extends its residence time on the ocular surface [8]. This interaction promotes corneal re-epithelialization and provides cytoprotection by facilitating cell migration and attachment [8, 9]. Therapeutic interventions targeting these components are primarily used to treat dry eye disease and persistent epithelial defects [2, 9]. In diabetic patients, alterations in GLUT-1 expression and matrix composition can lead to diabetic keratopathy, making these targets clinically significant for ocular surface repair [1, 5]. Monitoring efficacy typically involves assessing corneal staining and tear film stability [2, 8]. Overall, this target complex is essential for maintaining the physiological health and regenerative capacity of the ocular surface.
Carboxymethylcellulose binds to GLUT-1 via its glucopyranose subunits and to matrix proteins like collagen and fibronectin to promote epithelial cell adhesion and migration.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 1 (GLUT-1) and ocular surface extracellular matrix components (GLUT-1/ECM).